March 2019—EntroGen announced the availability of a lung cancer RNA panel intended for the qualitative detection of ALK, ROS1, and RET fusion genes, as well as MET exon 14 skipping mutations in human lung RNA.
The one-step reverse transcriptase PCR assay combines first-strand cDNA synthesis and subsequent amplification of mutant and reference genes, designed to minimize hands-on time and reduce the risk of introducing contaminants during preamplification. The three-step workflow produces results in less than two hours and detects 47 variants in eight reactions, the company reports.
The panel is compatible with several multichannel real-time PCR instruments capable of detecting FAM, VIC, and CY5 fluorescent probes and comes with complimentary data analysis software to automate reporting. The panel is for research use only.
EntroGen, 818-716-1070